thumbnail image
  • About TF
  • Why TF
  • Portfolio
  • Leadership
  • Contact Us
  • …  
    • About TF
    • Why TF
    • Portfolio
    • Leadership
    • Contact Us
  • About TF
  • Why TF
  • Portfolio
  • Leadership
  • Contact Us
  • …  
    • About TF
    • Why TF
    • Portfolio
    • Leadership
    • Contact Us
  • Portfolio Companies

    TF Capital has invested in nearly 100 companies, including successful NASDAQ, HKG, ChiNext Board and STAR market IPOs.

    Section image

    Zai Lab Limited

    (NASDAQ:ZLAB)
    research-based, commercial stage biopharmaceutical company based in China and the U.S. focused on bringing transformative medicines for oncology, immunology, neuroscience, and infectious diseases to patients in China and around the world.
    Click for More
    Section image

    Hua Medicine

    (HK:02552)
    drug development and commercialization company based in Shanghai, China. Hua Medicine focused on developing novel therapies for patients worldwide with unmet medical needs.
    Click for More
    Section image

    Henlius

    (HK:2696)
    a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases.
    Click for More
    Section image

    Rendu Biotechnology

    (SH:688193)
    focused on RNA detection technology innovation for 17 years, committed to providing more accurate and effective detection results and services for clinical use.
    Click for More
    Section image

    Sanyou Medical

    (SH:688085)

    a medical devices company specializing in the research, development, production, and sales of medical orthopedic implant consumables.

    Click for More
    Section image

    GemPharmatech

    (SH:688046)
    a leading contract research organization that provides genetically engineered mouse models and preclinical research services to the scientific community worldwide.
    Click for More
    Section image

    DreamCIS

    (KOSDAQ:223250)
    the largest CRO in Korea dedicated to provide clinical research services with over 1,200 successful projects to the pharmaceuticals, biotechnology, medical device and functional food industries.
    Click for More
    Section image

    Antegene Corporation

    (HK:06996)

    a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs.

    Click for More
    Section image

    InnoStar

    (SH:688710)
    support global pharmaceutical and biotech companies with drug discovery, ADME, PK/PD, toxicology, biomarkers, and bioanalysis services.
    Click for More
    Section image

    Structure

    (NASDAQ:GPCR)
    a clinical-stage biopharmaceutical company leveraging structure-based drug design to develop more accessible oral small molecule therapeutics for the treatment of chronic diseases including obesity and related diseases.
    Click for More
    Section image

    Abbisko

    (HK:02256)
    a R&D-driven, clinical-stage biopharmaceutical company dedicated to the discover and development of innnovative and differentiated small molecule oncology therapies.
    Click for More
    Section image

    Asieris

    (SH:688176)
    a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases.
    Click for More
    Section image

    PharmaResources

    (SZ:301230)
    a comprehensive one-stop service provider for new drug R&D as well as commercial production. We are dedicated to the drug discovery,pharmaceutical processes R&D, and the commercial manufacturing of APIs and intermediates.
    Click for More
    Section image

    Canbridge

    (HK:01228)
    a global biopharmaceutical company leveraging its foundation in China to develop and deliver life-changing therapeutics for rare diseases and rare oncology worldwide.
    Click for More
    Section image

    Genor Biopharma

    (HK:06998)
    an innovation-driven biopharma company with a pipeline of therapies covering the world's most prevalent cancer types (breast, lung, and gastrointestinal cancer) and hematological malignancies.
    Click for More
    Section image

    Smo Clinplus

    (SZ:301257)
    provides site management services to both local and global companies in research development in pharmaceuticals, medical devices, and health-related products.
    Click for More
    Section image

    FrontageLab

    (HK:01521)
    a global pharmaceutical development organization advancing drug discovery and development through integrated laboratory and clinical services.
    Click for More
    Section image

    HighTide

    (HK:02511)
    a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat patients with chronic metabolic diseases.
    Click for More
    Section image

    PegBio

    (HK: 02565)
    a biotechnology company focused on the in-house discovery and development of innovative therapies for chronic diseases with a particular emphasis on metabolic disorders.
    Click for More
    Section image

    GenFleet Therapeutics

    (HK: 02595)
    is dedicated to serving significant unmet medical needs globally in oncology and immunology.
    Click for More
Cookie Use
We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
Learn More